Targeting cytokines in inflammatory bowel disease (IBD) is a useful clinical approach.
Potential therapies for IBD include regulatory T cell transfer to restore cytokine balance …

Background The landscape of inflammatory bowel disease (IBD) treatment is rapidly
expanding with the development of new therapeutic options. Aim To review the mechanisms …

Highlights•Overview of colonic drug delivery systems.•Potential for local and systemic
delivery.•Key focus on metabolic activity of the colonic microbiota.•Challenges of microbiota …

Crohn's disease (CD) and ulcerative colitis (UC) are inflammatory bowel diseases (IBD)
characterized by intestinal inflammation. Increased intestinal levels of the proinflammatory …

ABSTRACT Introduction Ozoralizumab (Nanozora), a novel TNF inhibitor, was first approved
in Japan in September 2022 as a next-generation antibody for the treatment of rheumatoid …

Although the therapeutic armamentarium of Inflammatory bowel diseases (IBD) physicians
has expanded rapidly in recent years, a proportion of patients remain with a suboptimal …

Cytokines produced by immune cells contribute to the development and perpetuation of
inflammatory bowel disease (IBD), namely Crohn's disease and ulcerative colitis, by …

Although antibodies remain the most widely used tool for biomedical research, antibody
technology is not flawless. Innovative alternatives, such as Nanobody® molecules, were …

Inflammatory bowel disease (IBD) has been posed as a great worldwide health threat.
Having an onset during early adulthood, IBD is a chronic inflammatory disease …

Medicine has benefited greatly from the development of monoclonal antibody (mAb)
technology. First-generation mAbs have seen significant success in the treatment of major …